GSK’s RSV vaccine for adults 50-59 at increased risk accepted by FDA for Priority Review

GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results...

Vodafone Group service revenue momentum maintained, strategic partnerships with Microsoft and Accenture

Vodafone Group Plc has announced its Q3 FY24 trading update, highlighting strong service revenue momentum and strategic partnerships with Microsoft and Accenture. Read more...

GSK reaches confidential settlement with David Browne in Zantac case

GSK has reached a confidential settlement with David Browne, resolving a California state court case. The company will continue to defend itself in other Zantac cases...

BT Group reports strong growth in revenue and EBITDA, with increased customer demand

BT Group plc (LON:BT.A) has reported strong revenue and EBITDA growth, driven by the expansion of their full-fibre broadband and 5G networks. The company remains committed to its purpose and strategic focus, setting the stage for future growth...

AIM All Share Index

Trending Articles

Search

Search

Currency